Upjohn Company Profile

What is the competitive landscape for UPJOHN

UPJOHN has thirteen approved drugs.

There are three US patents protecting UPJOHN drugs.

Summary for Upjohn

US Patents:	3
Tradenames:	12
Ingredients:	9
NDAs:	13

Drugs and US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	LYRICA CR	pregabalin	TABLET, EXTENDED RELEASE;ORAL	209501-003	Oct 11, 2017	AB	RX	Yes	Yes	10,022,447*PED				Y
Upjohn	XANAX XR	alprazolam	TABLET, EXTENDED RELEASE;ORAL	021434-004	Jan 17, 2003	AB	RX	Yes	Yes
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-003	Dec 30, 2004	AB	RX	Yes	No
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-001	Mar 25, 1998	AB	RX	Yes	No
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-008	Dec 30, 2004	AB	RX	Yes	Yes
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-004	Dec 15, 2006	AB	RX	Yes	No

Expired US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-006	Dec 30, 2004	5,563,175
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-001	Approved Prior to Jan 1, 1982	4,508,726
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-001	Approved Prior to Jan 1, 1982	3,987,052
Upjohn	XANAX XR	alprazolam	TABLET, EXTENDED RELEASE;ORAL	021434-003	Jan 17, 2003	5,061,494
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-004	Nov 27, 1985	5,061,494
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-002	Dec 30, 2004	5,563,175

Paragraph IV (Patent) Challenges for UPJOHN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsules	2 mg and 4 mg		2007-07-30
	Capsules	50 mg		2008-03-21
	Oral Solution	20 mg/mL		2010-05-19
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02
	Tablets	20 mg and 40 mg		2010-03-29
	Extended-release Tablets	37.5 mg, 75 mg and 150 mg		2007-05-03
	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg		2008-12-30
	Extended-release Tablets	330 mg		2018-01-29
	Extended-release Tablets	330 mg		2018-01-29
	Tablets	25 mg and 50 mg		2006-09-27

International Patents for Upjohn Drugs

Country	Patent Number	Estimated Expiration
Morocco	30135
New Zealand	567414
Spain	2449231
Denmark	1945186
Peru	20070693
European Patent Office	1945186

Supplementary Protection Certificates for Upjohn Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0592438	02C0013	France		PRODUCT NAME: ELETRIPTAN HYDROBROMIDE; NAT. REGISTRATION NO/DATE: NL 26625 20011105; FIRST REGISTRATION: LI - IKS 55218 20001214
3461484	301101	Netherlands		PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108
0364417	9690031-1	Sweden		PRODUCT NAME: LATANOPROST
3461484	2021C/515	Belgium		PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
1003503	05C0048	France		PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
0247633	C970034	Netherlands		PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Upjohn